Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 286

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Liver Transplantation for Advanced Hepatocellular Carcinoma Using Poor Tumor Differentiation on Biopsy as an Exclusion Criterion

DuBay, Derek, Sandroussi, Charbel, Sandhu, Lakhbir, Cleary, Sean, Guba, Markus, Cattral, Mark S., McGilvray, Ian, Ghanekar, Anand, Selzner, Markus, Greig, Paul D., Grant, David R.·2011·Annals of Surgery

Abstract

In Brief Background: Liberal acceptance criteria are used when offering liver transplantation (LTx) for treatment of hepatocellular carcinoma (HCC) at our center. This provides a unique opportunity to assess outcomes in a large North American series of patients with advanced tumors. Objective: We hypothesized that acceptable survival rates can be achieved with LTx for any size or number of HCC provided that (a) imaging studies ruled out vascular invasion; (b) the HCC was confined to the liver; and (c) the HCC was not poorly differentiated on biopsy. Methods: Survival, based on pretransplant imaging staging, was compared between 189 Milan Criteria (M) and 105 beyond Milan Criteria (M+) HCC patients who received an LTx between 1996 and 2008. Results: Imaging understaged 30% of the M group and overstaged 23% of the M+ group. There was no difference in the 5-year overall survival in the M (72%) and M+ (70%) groups or 5-year disease-free survival in the M (70%) and M+ (66%) groups. The introduction of a protocol for a biopsy to exclude patients with poorly differentiated tumors and use of aggressive bridging therapy improved overall survival in the M+ group (P = 0.034). Serum alpha-fetoprotein more than 400 at LTx was associated with poorer disease-free survival (hazard ratio: 2.3; P = 0.031). Conclusions: Cross-sectional imaging did not reliably stage patients with HCC for LTx. A protocol using a biopsy to exclude poorly differentiated tumors and aggressive bridging therapy achieved excellent survival rates with LTx for otherwise incurable advanced HCC, irrespective of tumor size and number. We examined the survival of a large cohort of patients transplanted for advanced hepatocellular carcinoma. Macrovascular invasion was the only criteria used to exclude patients from transplantation; tumor number and size were not considered. The 5-year overall survival was excellent in both Milan (72%) and beyond Milan Criteria (70%) groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/sla.0b013e31820508f1

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 28 references

Cited by

See all 286

Metadata

Authors
DuBay, D., Sandroussi, C., Sandhu, L., Cleary, S., Guba, M., Cattral, M. S., McGilvray, I., Ghanekar, A., Selzner, M., Greig, P. D., & Grant, D. R.
Venue
Annals of Surgery
Published
2011-01
Volume
253
Issue
1
Pages
166-172
ISSN
0003-4932 (ISSN-L)
OpenAlex
W2327442791
Cited by
286
References
28
FWCI
9.97
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Liver Transplantation for Advanced Hepatocellular Carcinoma Using Poor Tumor Differentiation on Biopsy as an Exclusion Criterion. https://app.cochat.ai/papers/10.1097/sla.0b013e31820508f1
The paper
DuBay, D., Sandroussi, C., Sandhu, L., Cleary, S., Guba, M., Cattral, M. S., McGilvray, I., Ghanekar, A., Selzner, M., Greig, P. D., & Grant, D. R. (2011). Liver Transplantation for Advanced Hepatocellular Carcinoma Using Poor Tumor Differentiation on Biopsy as an Exclusion Criterion. Annals of Surgery. https://doi.org/10.1097/sla.0b013e31820508f1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.